CYCN News and Press, Cyclerion Therapeutics Inc. From 10/14/20

Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...

Cyclerion Therapeutics (CYCN) -41% after Phase 2 STRONG-SCD study results in patients with Sickle Cell Disease.Sorrento Therapeutics (SRNE) -12%.Aethlon Medical (AEMD) -11%.Enzo Biochem ENZ -10% on FQ4 earnings results.Auris Medical Holding (EARS) -10%.SOS  ...

Cyclerion Therapeutics (CYCN) has announced results from its Phase 1 translational pharmacology study, evaluating IW-6463 for central nervous system ((CNS)) disorders.This 24-subject, 15-day crossover study, confirmed and extended results seen in earlier Phase 1 studies. Subjects receivi...

CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, today announced top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator...

Showed significant i mprovements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases Confirmed blood-brain-barrier penetration, desired CNS exposure levels, target engagement and ...

Results from phase 2 STRONG-SCD study using olinciguat for the treatment of patients with sickle cell disease expected before the end of 2020. The global sickle cell disease market is expected to reach $5.5 billion by 2023. IW-6463 is being used to target patients with Alzheimer's...

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Compa...

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that it has been awarded a grant from the Alzheimer's Association’s Part ...

Cyclerion Therapeutics (NASDAQ: CYCN ) : Q2 net loss of $20M More news on: Cyclerion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-   IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   - -  Completed $24 million equity private placement to accelerate clinical development of IW-6463 for the CNS diseases MELAS (Mitochon...